Respiratory syncytial virus often causes severe respiratory disease. This condition places a high burden on older adults. Therefore, clinical updates regarding RSV vaccines for adults are essential for physicians. Recent reviews highlight the significant protection these immunizations offer to vulnerable populations. Specifically, these vaccines target individuals who are not pregnant or immunocompromised.
Clinical Efficacy of RSV Vaccines for Adults
Protein subunit vaccines demonstrate impressive results in preventing severe outcomes. Researchers found that these vaccines reduce RSV-related hospitalizations by 83.3 percent. Furthermore, they decrease the risk of severe illness by 94.1 percent in older adults. Notably, these benefits apply primarily to patients aged 60 years and above. However, the vaccines show no significant effect on all-cause mortality rates. Consequently, clinicians should prioritize hospitalization prevention as the main clinical goal. mRNA vaccines also show promise but require more long-term data for comparison. Nevertheless, the existing evidence for protein subunit options remains moderate to high in certainty.
Safety and Serious Adverse Events
Safety remains a critical factor for any new vaccine recommendation. Fortunately, serious adverse events do not differ significantly between vaccine and placebo groups. Specifically, protein subunit vaccines maintain a safety profile comparable to no vaccination. Additionally, mRNA vaccines show no increase in the incidence of serious harms. These findings provide reassurance to healthcare providers and their patients. Therefore, the risk-benefit ratio remains favorable for older adults with comorbidities. Doctors should still monitor patients for local reactions after administration. Moreover, ongoing surveillance will continue to track rare neurologic events.
Frequently Asked Questions
Q1: Who should receive the RSV vaccine based on this review?
Adults aged 60 and older derive the most benefit from protein subunit RSV vaccines. These patients see a significant reduction in hospitalizations and severe respiratory symptoms.
Q2: Are there any serious safety concerns with mRNA RSV vaccines?
Studies indicate that mRNA vaccines show no difference in serious adverse events compared to placebos. However, data on their overall efficacy remains less extensive than subunit vaccines.
Q3: Does the RSV vaccine reduce the overall death rate?
Current evidence suggests that RSV vaccines do not significantly impact all-cause mortality. Their primary value lies in preventing severe illness and costly hospital admissions.
References
- Moser ITK et al. Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Ann Intern Med. 2026 Mar 03. doi: 10.7326/ANNALS-25-05536. PMID: 41771131.
- NIH. Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older in India and Southeast Asia. 2025.
- CDC. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna mRNA RSV Vaccine in older adults. 2024.